FOX BIZ NEWS: Biogen's stock soars as Alzheimer's drug costs revealed after FDA approval


Biogen's stock soars as Alzheimer's drug costs revealed after FDA approval



Biogen Inc. shares were on track for their biggest gain on record after the drugmaker released pricing for its recently approved Alzheimer’s drug Aduhelm.

Comments

Popular posts from this blog

Covid live: Record 50,000+ infections on Sunday

Impact of pandemic? Women jobseekers fell by 34% in 2021

SC slams trial courts for seeking needless custody